CD274 and non-small cell lung carcinoma: Our finding suggests that neoadjuvant PD-(L)1 blockade plus immunotherapy might be explored in NSCLC patients harbouring a specific oncogene alteration type, which warrants further verification in clinical trials with larger cohorts.